Method of treating bone cancers
AssigneeAlaMab Therapeutics, Inc.
InventorsYanfeng Zhang, Xiugao Yang, Yongyong Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in patients who previously failed at least one line of therapy for treatment of osteosarcoma. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.
Claims40
A method of treating a bone cancer in a subject in need thereof, comprising administering to the subject at least one dose of an anti-connexin 43 (Cx43) antibody, or antigen binding fragment thereof, wherein the anti-Cx43 antibody comprises
- a heavy chain variable region comprising HCDR amino acid sequences:
- HCDR1:
- SEQ ID NO:
- 1;
- HCDR2:
- SEQ ID NO:
- 2;
- HCDR3:
- SEQ ID NO:
- 3;
- and
- a light chain variable region comprising LCDR amino acid sequences:
- LCDR1:
- SEQ ID NO:
- 4;
- LCDR2:
- SEQ ID NO:
- 5;
- LCDR3:
- SEQ ID NO:
- 6.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a bone cancer in a subject in need thereof, comprising administering to the subject at least one dose of an anti-connexin 43 (Cx43) antibody, or antigen binding fragment thereof, wherein the at least one dose of the anti-Cx43 antibody is about 0.001 mg/kg to about 300 mg/kg, about 1 mg/kg, about 3 mg/kg, about 6 mg/kg, about 12 mg/kg, about 18 mg/kg, about 24 mg/kg, about 30 mg/kg, or about 36 mg/kg.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.